You are viewing an incomplete version of our website. Please click to reload the website as full version.

Vimentin antibody (VIM)

Details for Product anti-VIM Antibody No. ABIN967252, Supplier: Log in to see
Antigen
  • vime
  • CTRCT30
  • cb28
  • vim
  • vim1
  • vim2
  • VIM
  • Vimentin
  • vimentin
  • Vimentin
  • vimentin-like
  • VIM
  • vim
  • vime
  • Vim
  • vim-a
  • LOC100522394
Alternatives
anti-Human Vimentin antibody for Immunohistochemistry (Frozen Sections)
Reactivity
Human
838
364
311
219
137
132
114
83
79
50
48
41
41
36
30
10
7
6
5
5
4
3
3
2
2
1
1
1
1
1
Host
Mouse
518
295
29
14
12
8
7
Clonality (Clone)
Monoclonal ()
Conjugate
This Vimentin antibody is un-conjugated
27
27
23
20
15
14
12
11
11
11
11
11
11
11
11
9
5
5
5
3
3
3
3
3
3
3
3
3
3
2
2
Application
Immunohistochemistry (IHC), ELISA, Western Blotting (WB)
665
288
284
265
237
221
216
107
82
40
15
14
13
10
8
8
5
3
3
3
1
1
1
1
1
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Immunogen Purified recombinant fragment of Vimentin expressed in E. Coli.
Clone 9E7E7-5G3F10-5G3F10E5
Isotype IgG1
Purification Ascitic fluid
Alternative Name Vimentin (VIM Antibody Abstract)
Background Vimentin is the major subunit protein of the intermediate filaments of mesenchymal cells. It is believed to be involved with the intracellular transport of proteins between the nucleus and plasma membrane. Vimentin has been implicated to be involved in the rate of steroid synthesis via its role as a storage network for steroidogenic cholesterol containing lipid droplets. Vimentin phosphorylation by a protein kinase causes the breakdown of intermediate filaments and activation of an ATP and myosin light chain dependent contractile event. This results in cytoskeletal changes that facilitate the interaction of the lipid droplets within mitochondria, and subsequent transport of cholesterol to the organelles leading to an increase in steroid synthesis. Immunohistochemical staining for Vimentin is characteristic of sarcomas (of neural, muscle and fibroblast origin) compared to carcinomas which are generally negative. Melanomas, lymphomas and vascular tumors may all stain for Vimentin. Vimentin antibodies are thus of value in the differential diagnosis of undifferentiated neoplasms and malignant tumors. They are generally used with a panel of other antibodies including those recognising cytokeratins, lymphoid markers, S100, desmin and neurofilaments.
Synonyms: FLJ36605, VIM
Gene ID 7431
Research Area Lineage Markers, Cytoskeleton, Neural Stem Cell marker, Cell/Tissue Markers
Pathways TCR Signaling, Caspase Cascade in Apoptosis
Application Notes Western Bloting: 1/500 - 1/2000.
Immunohistochemistry: 1/200 - 1/1000.
ELISA: Propose dilution 1/10000.
Not yet tested in other applications.
Determining optimal working dilutions by titration test.
Restrictions For Research Use only
Format Liquid
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C
Product cited in: Vanzi: "Freedom at home: state constitutions and Medicaid funding for abortions." in: New Mexico law review, Vol. 26, Issue 3, pp. 433-54, 2005 (PubMed).

Background publications Seshadri, Raymond, Leong, Horsfall, McCaul: "Vimentin expression is not associated with poor prognosis in breast cancer." in: International journal of cancer. Journal international du cancer, Vol. 67, Issue 3, pp. 353-6, 1996 (PubMed).

Chu, Seftor, Romer, Hendrix: "Experimental coexpression of vimentin and keratin intermediate filaments in human melanoma cells augments motility." in: The American journal of pathology, Vol. 148, Issue 1, pp. 63-9, 1996 (PubMed).

Essa, el Tatawi, Hamdi, Arafa: "Vimentin expression in different types of breast carcinoma immunohistochemical study." in: Journal of the Egyptian Society of Parasitology, Vol. 26, Issue 2, pp. 433-42, 1996 (PubMed).